2C-T-17


2C-T-17, also known as 4-sec-butylthio-2,5-dimethoxyphenethylamine or as Nimitz, is a psychedelic drug of the phenethylamine and 2C families. It is taken orally.
2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991. Shortly after this, Shulgin described 2C-T-17 in greater detail in his 1991 book PiHKAL.

Use and effects

According to Alexander Shulgin in his book PiHKAL, 2C-T-17's dose range is 60 to 100mg and its duration is 10 to 15hours. Its onset is 1hour and peak effects occurred after 3hours. 2C-T-17 has been described as a "truly heavy psychedelic" but as producing no psychedelic visuals and very little in the way of perceptual changes. User reports described it as having pronounced psychoactive effects but had difficulty describing exactly what those effects were.

Toxicity

The toxicity of 2C-T-17 is not well-documented. It is much less potent than 2C-T-7, but it may be expected that at very high doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.

Pharmacology

Pharmacodynamics

The mechanism of action that produces 2C-T-17's hallucinogenic effects has not been specifically established, however it is most likely to result from action as a serotonin 5-HT2A receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.

Chemistry

2C-T-17 is the 2 carbon homologue of Aleph-17, which has never been synthesized. The full chemical name is 2-ethanamine. The drug has structural properties similar to drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-8.

History

2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in a journal article in 1991. Shortly thereafter, it was described in greater detail by Shulgin in his 1991 book PiHKAL.

Society and culture

Legal status

Canada

As of October 31, 2016, 2C-T-17 is a controlled substance in Canada.

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.

United States

2C-T-17 is not illegal, but possession and sales of 2C-T-17 could be prosecuted under the Federal Analog Act in the United States because of its structural similarities to 2C-T-7.